What biomarker testing is recommended for locally advanced Breast Cancer

Biomarker Testing for Locally Advanced Breast Cancer

Based on current clinical guidelines, here's what biomarker testing is typically recommended for locally advanced breast cancer:

Standard Biomarker Testing

According to NCCN Guidelines for Invasive Breast Cancer, your care team will recommend biomarker testing on a sample from your tumor biopsy. The standard tests include:

Hormone Receptor Status (Essential)

• Estrogen Receptor (ER) and Progesterone Receptor (PR) testing
• These determine if your cancer cells use hormones to grow
• Results guide whether hormone-blocking therapies will be effective

HER2 Status (Essential)

• Tests for HER2 protein overexpression or gene amplification
• HER2-positive cancers respond to targeted HER2 therapies
• This is a critical decision point for treatment planning

Additional Tumor Mutation Testing

The NCCN Guidelines recommend testing for specific DNA mutations that can be targeted with therapies, including:

• PIK3CA mutations – can be treated with targeted therapies like alpelisib
• AKT1 mutations – targetable with specific inhibitors
• PTEN alterations – may guide treatment selection
• ESR1 mutations – typically tested in hormone receptor-positive tumors
• NTRK and RET fusions – rare but actionable if present

Testing Methods

According to NCCN Guidelines, these tests use various laboratory methods:

• Next-generation sequencing (NGS) – comprehensive DNA analysis
• Immunohistochemistry (IHC) – protein detection
• FISH (Fluorescence In Situ Hybridization) – gene amplification detection
• PCR (Polymerase Chain Reaction) – sensitive mutation detection

Germline (Inherited) Testing

The NCCN Guidelines recommend germline BRCA1/2 testing for patients with breast cancer, as this information affects:

• Your personal cancer risk
• Family members' risk
• Treatment options (PARP inhibitors if mutations present)
• Genetic counseling needs

Tumor Markers (Blood Tests)

Your doctor may also check blood-based tumor markers like:

• CA 15-3 and CA 27.29
• These can help monitor treatment response over time
• However, they're not reliable for initial diagnosis

---

Questions to Ask Your Oncology Team

1. Which biomarker tests have been done on my tumor, and what were the results?
2. Are there any actionable mutations that would change my treatment approach?
3. Do I need germline BRCA testing, and if so, when should that be done?
4. Will you be doing liquid biopsy (blood-based testing) in addition to tissue testing?
5. How will these biomarker results affect my treatment plan?

---

Why This Matters

Biomarker testing transforms breast cancer from a "one-size-fits-all" disease into a personalized medicine approach. Your specific biomarker profile determines which treatments are most likely to work for YOUR cancer, potentially improving outcomes while minimizing unnecessary side effects.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.